In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line
- PMID: 2121738
- PMCID: PMC12201276
- DOI: 10.1007/BF01612991
In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line
Abstract
Resistance of a rat ovarian tumor cell line (O-342/DDP) to cisplatin was induced in vitro by stepwise increase of cisplatin concentrations. Both chemosensitive parental cells (O-342) and resistant O-342/DDP cells grow in a monolayer and enter log-phase growth about 24 h after seeding (cell population doubling time in log-phase growth is about 24 h). O-342/DDP cells show a 33-fold resistance to cisplatin as compared to O-342 cells (ID50 = 33 microM in O-342/DDP vs 1 microM in O-342 cells). The intracellular total glutathione (GSH + GSSG) of O-342/DDP cells was twice as high as that of O-342 cells (3.04 vs 1.37 nmol/10(6) cells), while the intracellular GSSG was increased by 26% in O-342/DDP cells compared to O-342 cells. DNA interstrand crosslinks were found to be 8.5 times higher in O-342 cells than in O-342/DDP cells (204 vs 24 rad equiv.), following cisplatin treatment. DNA single-strand breaks were approximately doubled in the sensitive line as compared to the resistant line following exposure to cisplatin. Chromosome analysis uncovered a change in the karyotype of O-342/DDP cell as compared to O-342 cells. In the sensitive line hyperploid (3n) clones, in the resistant line near-diploid clones predominated. Both DL-buthionine-(S,R)-sulfoximine and 3-aminobenzamide were able to sensitize the resistant line towards cisplatin. Thus, the present results suggest that mechanisms for cisplatin resistance in this tumor line apparently are multi-factorial, and include a higher intracellular GSH content and an increased repair activity.
Similar articles
-
Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line.J Cancer Res Clin Oncol. 1991;117(6):539-42. doi: 10.1007/BF01613285. J Cancer Res Clin Oncol. 1991. PMID: 1744159 Free PMC article.
-
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.J Cancer Res Clin Oncol. 1996;122(11):665-70. doi: 10.1007/BF01209029. J Cancer Res Clin Oncol. 1996. PMID: 8898976 Free PMC article.
-
Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.J Cancer Res Clin Oncol. 1992;119(1):28-34. doi: 10.1007/BF01209484. J Cancer Res Clin Oncol. 1992. PMID: 1400562 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. Cochrane Database Syst Rev. 2022. PMID: 35170751 Free PMC article.
Cited by
-
Modulation of cis-diamminedichloroplatinum(II) resistance: a review.Br J Cancer. 1992 Aug;66(2):227-38. doi: 10.1038/bjc.1992.249. Br J Cancer. 1992. PMID: 1503895 Free PMC article. Review.
-
Anticancer Alkaloids from Trees: Development into Drugs.Pharmacogn Rev. 2016 Jul-Dec;10(20):90-99. doi: 10.4103/0973-7847.194047. Pharmacogn Rev. 2016. PMID: 28082790 Free PMC article. Review.
-
Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.Cell Biol Toxicol. 1995 Oct;11(5):273-81. doi: 10.1007/BF00757625. Cell Biol Toxicol. 1995. PMID: 8608408
-
Revisiting the BRCA-pathway through the lens of replication gap suppression: "Gaps determine therapy response in BRCA mutant cancer".DNA Repair (Amst). 2021 Nov;107:103209. doi: 10.1016/j.dnarep.2021.103209. Epub 2021 Aug 13. DNA Repair (Amst). 2021. PMID: 34419699 Free PMC article. Review.
-
Karyotypic change from heteroploidy to near diploidy associated with development of cisplatin resistance in a rat ovarian tumour cell line.J Cancer Res Clin Oncol. 1991;117(6):539-42. doi: 10.1007/BF01613285. J Cancer Res Clin Oncol. 1991. PMID: 1744159 Free PMC article.
References
-
- Andrews PA, Murphy MP, Howell SB (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45:6250–6253 - PubMed
-
- Bedford P, Walker MC, Sharma HL, Perera A, Mcauliffe CA, Masters JRW, Hill BT (1987) Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II). Chem Biol Interact 61:1–15 - PubMed
-
- Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, Mckoy WM, Young RC, Ozols RF (1987) Characterization of acis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414–418 - PubMed
-
- Chen G, Frei E, Zeller WJ (1989) Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. Cancer Lett 46:207–211 - PubMed
-
- Eastman A, Schulte N (1988) Enhanced DNA repair as a mechanism of resistance tocis-diamminedichloroplatinum(II). Biochemistry 27:4730–4734 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials